Ken Griffin Macrogenics Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $993 - $5,553	300 Added 0.53%	56,900 $241,000
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $509,994 - $1.12 Million	52,200 Added 1186.36%	56,600 $833,000
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $18,368 - $41,451	4,100 Added 1366.67%	4,400 $42,000
Q3 2023 Nov 14, 2023	SELL	$4.48 - $6.19 $50,176 - $69,328	-11,200 Reduced 97.39%	300 $1,000
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $79,926 - $130,442	-17,300 Reduced 60.07%	11,500 $61,000
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $112,788 - $169,416	23,400 Added 433.33%	28,800 $206,000
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $18,036 - $37,692	5,400 New	5,400 $36,000

154

60.6M

218K

259K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $203M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.